Core Viewpoint - Kamada Ltd. is actively participating in key healthcare investment conferences to enhance investor engagement and showcase its growth strategy in the biopharmaceutical sector [1][2]. Company Overview - Kamada Ltd. is a global biopharmaceutical company specializing in rare and serious conditions, particularly in the specialty plasma-derived therapies field [3]. - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB, CYTOGAM, GLASSIA, WINRHO SDF, VARIZIG, and HEPAGAM B, along with other proprietary products [3]. Growth Strategy - The company's growth strategy is built on four primary pillars: 1. **Organic Growth**: Focus on commercialization and life cycle management of proprietary products, including the launch of several biosimilar products in Israel [3]. 2. **Business Development**: Pursue new business opportunities through in-licensing, collaborations, and mergers and acquisitions to enhance its product portfolio [3]. 3. **Plasma Collection Expansion**: Increase plasma collection operations to support revenue growth and meet the demand for hyper-immune plasma, with three operating centers in Texas [3]. 4. **R&D Advancements**: Leverage manufacturing and research expertise to develop additional product candidates, with a focus on the InnovAATe clinical trial for Inhaled AAT [3]. Conference Participation - CEO Amir London will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, and at the H.C. Wainwright 27 Annual Global Investment Conference on September 8, 2025, with opportunities for one-on-one investor meetings [2][3].

Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in specialty plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B® [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3] Financial Results Announcement - Kamada will release its financial results for the first quarter ending March 31, 2025, prior to the opening of U.S. financial markets on May 14, 2025 [1] - An investment community conference call will be held on the same day at 8:30am ET to discuss the results and answer questions [2] Growth Strategy - The company aims for organic growth through commercialization and life cycle management of its proprietary products [3] - Kamada is pursuing new business development opportunities, including in-licensing, collaboration, and M&A to enhance its product portfolio [3] - The company is expanding plasma collection operations to support revenue growth and meet increasing demand for hyper-immune plasma [3] - Kamada is advancing the development of additional product candidates, with a focus on unmet medical needs, including the InnovAATe clinical trial for Inhaled AAT [3]